Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2016
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMBER
- 09 Sep 2016 Status changed from recruiting to completed, according to results published in the Alimentary Pharmacology and Therapeutics.
- 09 Sep 2016 Results published in the Alimentary Pharmacology and Therapeutics.
- 17 Apr 2016 Preliminary results (n=209) of the predictors of hepatic de-compensation, presented at The International Liver Congress™ 2016